Long-term follow-up of patients with refractory systemic lupus erythematosus during rituximab treatment
- 作者: Tsanian M1, Solov'ev S1, Torgashina A1, Aleksandrova E1, Radenska-Lopovok S1, Nikolaeva E1, Khrennikov I.1, Nasonov E1
-
隶属关系:
- ФГБУ "НИИ ревматологии им. В.А. Насоновой" РАМН, Москва
- 期: 卷 86, 编号 5 (2014)
- 页面: 40-49
- 栏目: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/31482
- ID: 31482
如何引用文章
全文:
详细
作者简介
M Tsanian
ФГБУ "НИИ ревматологии им. В.А. Насоновой" РАМН, Москва
Email: maridoc@bk.ru
S Solov'ev
ФГБУ "НИИ ревматологии им. В.А. Насоновой" РАМН, Москва
A Torgashina
ФГБУ "НИИ ревматологии им. В.А. Насоновой" РАМН, Москва
E Aleksandrova
ФГБУ "НИИ ревматологии им. В.А. Насоновой" РАМН, Москва
S Radenska-Lopovok
ФГБУ "НИИ ревматологии им. В.А. Насоновой" РАМН, Москва
E Nikolaeva
ФГБУ "НИИ ревматологии им. В.А. Насоновой" РАМН, Москва
Ia Khrennikov
ФГБУ "НИИ ревматологии им. В.А. Насоновой" РАМН, Москва
E Nasonov
ФГБУ "НИИ ревматологии им. В.А. Насоновой" РАМН, Москва
参考
- Клюквина Н.Г., Насонов Е.Л., Насонова В.А. Системная красная волчанка. Ревматология, национальное руководство. М: ГЭОТАР-Медиа 2008: 419-446.
- D´Cruz D.P., Khamashta M.A., Hughes G.R.V. Systemic lupus erythematosus. Lancet 2007; 369: 587-596.
- Cervera R., Khamashta M.A., Font J. et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: A comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore). 2003; 82: 299-308.
- Doria A., Iaccarino L., Ghirardello A. et al. Long-term prognosis and causes of death in systemic lupus erythematosus. Am J Med 2006; 119: 700-706.
- Mok C.C., Kwok C.L., Ho L.Y. et al. Life expectancy, standardized mortality ratios, and causes of death in six rheumatic diseases in Hong Kong, China. Arthritis Rheum 2011; 63: 1182-1189.
- Eder L., Urowitz M.B., Gladman D.D. Damage in lupus patients-what have we learned so far? Lupus 2013; 22: 1225-1231.
- Zonana-Nacach A., Barr S.G., Magder L.S., Petri M. Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum 2000; 43: 1801-1808.
- Duxbury B., Combescure C., Chizzolini С. Rituximab in systemic lupus erythematosus: an updated systematic review and meta-analysis. Lupus 2013; 10: 1-15.
- Leandro M.J., Cambridge G., Edwards J.C. et al. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology (Oxford) 2005; 44: 1542-1545.
- Merrill J., Buyon J., Furie R. et al. Assessment of flares in lupus patients enrolled in a phase II/III study of rituximab (EXPLORER). Lupus 2011; 20: 709-716.
- Rovin B.H., Furie R., Latinis K. et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 2012; 64: 1215-1226.
- Weidenbusch М., Rоmmele С., Schrоttle А., Anders Н. Beyond the LUNAR trial. Eficacy of rituximab in refractory lupus nephritis. Nephrol Dial Transplant 2013; 28: 106-111.
- Насонова В.А. Системная красная волчанка. М 1972.
- Насонова В.А., Астапенко М.Г. Клиническая ревматология. М 1989; 320.
- Gladman D.D., Ibanez D., Urowitz M.B. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002; 29: 288-291.
- Торгашина А.В. Влияние анти-В-клеточной терапии на клинические, иммунологические и морфологические показатели активности у больных системной красной волчанкой: Дис. ... канд. мед. наук. М 2011: 70.
- Mosca M., Bombardieri S. Assessing remission in systemic lupus erythematosus. Clin Exp Rheumatol 2006; 24 (43): 99-104.
- Petri M., Kasitanon N., Lee S.S. et al. Renal Activity/Response Exercise. Development of a Renal Activity Score and Renal Response Index. Arthritis Rheum 2008; 58 (6): 1784-1788.
- Chambers S.A., Isenberg D.A. Anti-B cell therapy (Rituximab) in the treatment of autoimmune disease. Lupus 2005; 14: 210-214.
- Silverman G.J. Anti-CD20 therapy in systemic lupus erythematosus: a step closer to the clinic. Arthritis Rheum 2005; 52: 371-377.
- Nebro F.A., Fuente J.M., Carren L. et al. Multicenter longitudinal study of B-lymphocyte depletion in refractory systemic lupus erythematosus: The LESIMAB study. Lupus 2012; 21: 1063-1076.
- Terrier B., Amoura Z., Ravaud P. et al. Safety and efficacy of rituximab in systemic lupus erythematosus: Results from 136 patients from the French AutoImmunity and Rituximab registry. Arthritis Rheum 2010; 62: 2458-2466.
- Witt M., Grunke M., Proft F. et al. Clinical outcomes nd safety of rituximab treatment for patients with systemic lupus erythematosus (SLE) - results from a nationwide cohort in Germany (GRAID). Lupus 2013; 22: 1142-1149.
- Smith K.G., Jones R.B., Burns S.M., Jayne D.R.W. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis. Remission, relapse and re-treatment. Athritis Rheum 2006; 54 (9): 970-982.
- Мendoza C.A., Valdes R.M., Orta E.C. et al. Treating severe systemic lupus erythematosus with rituximab. An open study. Rheumatol Clin 2009; 5 (4): 147-152.
- Perez M.V., Castro B.H., Saharopulos O.P. et al. Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Res Ther 2006; 8: 83-88.
- Gottenberg J.E., Guillevin L., Lambotte O. et al. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis 2005; 64: 913-920.
- Tanaka Y., Yamamoto K., Takeuchi T. et al. A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus. Mod Rheumatol 2007; 17: 191-197.
- Diaz-Lagares C., Croca S., Sangle S. et al. Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts. Autoimmun Rev 2012; 11: 357-364.
- Terrier B., Amoura Z., Ravaud P. et al. Safety and efficacy of rituximab in systemic lupus erythematosus: Results from 136 patients from the French AutoImmunity and Rituximab registry. Arthritis Rheum 2010; 62: 2458-2466.
- Casals M.R., Soto M.J., Cuadrado M.J., Khamashta M.A. Rituximab in systemic lupus erythematosus. A systematic review of off-label use in 188 cases. Lupus 2009; 18: 767-776.
- Davies R.J., Sangle S.R., Jordan N.P. et al. Rituximab in the treatment of resistant lupus nephritis: Therapy in rapidly progressive crescentic lupus nephritis. Lupus 2013; 22: 574-582.
- Perez M.V., Castro B.H., Saharopulos O.P. et al. Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Res Ther 2006; 8: 83-88.
- Josdottir Т., Zickert А., Sundelin В. et al. Long-term follow-up in lupus nephritis patients treated with rituximab - clinical and histopatological response. Rheumatology (Oxford, England). 2013; 52 (5): 847-855.
- Tokunaga M., Saito K., Kawabata D. et al. Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis 2007; 66: 470-475.
- Marks S.D., Patey S., Brogan P.A. et al. B lymphocyte depletion therapy with refractory systemic lupus erythematosus. Arthritis Rheum 2005; 52: 3168-3174.
- Looney R.J., Anolik J.H., Campbell D. et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 2004; 50: 2580-2589.
- Ng K.P., Cambridge G., Leandro M.J. et al. B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response. Ann Rheum Dis 2007; 66: 1259-1262.
- Lindholm C., Borjesson-Asp K., Zendjanchi K. et al. Longterm clinical and immunological effects of anti-CD-20 treatment in patients with refractory systemic lupus erythematosus. J Rheumatol 2008; 35: 826-833.
- Chen H., Zheng W., Su J. et al. Low-dose rituximab therapy for refractory thrombocytopenia in patients with systemic lupus erythematosus - a prospective pilot study. Rheumatol Clin 2006; 2: 23-30.
- Gunnarsson I., Sundelin B., Jonsdottir T. et al. Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis. Arthritis Rheum 2007; 56: 1263-1272.
- Hofmann S.C., Leandro M.J., Morris S.D., Isenberg D.A. Effect of rituximab-based depletion therapy on skin manifestations of lupus erythematosus - report of 17 cases and review of the literature. Lupus 2013; 22: 932-939.
- Anolik J.H., Barnard J., Cappione A. et al. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum 2004; 50: 3580-3590.
- Leandro M.J., Edwards J.C., Cambridge G. et al. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum 2002; 46: 2673-2677.
- Leandro M.J., Cambridge G., Edwards J.C. et al. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology (Oxford) 2005; 44: 1542-1545.
- Fernandez-Nebro A., Marenco de la Fuente J.L., Carreno L. et al. Multicenter longitudinal study of B-lymphocyte depletion in refractory systemic lupus erythematosus: the LESIMAB study. Lupus 2012; 21: 1063-1076.
- Catapano F., Chaudhry A.N., Jones R.B. et al. Long-term efficacy and safety of rituximab in refractory and relapsing systemic lupus erythematosus. Nephrol Dial Transplant. 2010; 25; 3586-3592.
- Hofmann S.C., Leandro M.J., Morris S.D., Isenberg D.A. Effect of rituximab-based depletion therapy on skin manifestations of lupus erythematosus - report of 17 cases and review of the literature. Lupus 2013; 22: 932-939.